gquadruplex
noncanon
nucleic
acid
secondari
structur
form
within
guaninerich
strand
regulatori
genom
region
extens
describ
human
genom
especi
telomer
oncogen
promot
recent
year
presenc
virus
attract
increas
interest
inde
report
sever
virus
includ
involv
recent
epidem
zika
ebola
virus
viral
usual
locat
regulatori
region
genom
implic
control
key
viral
process
case
involv
also
viral
latenc
context
ligand
develop
test
tool
studi
complex
mechan
viral
life
cycl
therapeut
agent
gener
ligand
show
promis
antivir
activ
mechan
action
genom
transcript
level
review
aim
provid
updat
closeup
literatur
virus
current
state
art
ligand
antivir
research
also
report
particular
focu
structur
physicochem
requir
optim
biolog
activ
achiev
todo
field
discuss
gquadruplex
nucleic
acid
secondari
structur
form
within
dna
rna
guanin
g
rich
strand
two
gtetrad
stack
top
coordin
monoval
cation
k
na
tetrad
compos
four
g
residu
link
sugarphosph
backbon
connect
hoogsteentyp
hydrogen
bond
highli
polymorph
structur
whose
topolog
influenc
variat
strand
stoichiometri
polar
well
natur
length
loop
locat
sequenc
fold
intramolecularli
singl
grich
strand
intermolecularli
dimer
tetramer
separ
filament
research
biolog
relev
mainli
focus
monomolecular
howev
intermolecular
gain
increas
attent
strand
orient
defin
parallel
antiparallel
mix
topolog
directli
correl
conform
state
anti
syn
glycosid
bond
g
base
sugar
anti
conform
character
parallel
fold
antiparallel
found
adopt
syn
anti
orient
figur
rna
mostli
lock
parallel
conform
due
hydroxyl
group
sugar
exclus
allow
anti
orient
dna
principl
character
higher
topolog
divers
even
though
major
dna
examin
far
adopt
parallel
topolog
comput
analysi
use
differ
algorithm
indic
around
potenti
sequenc
may
form
human
genom
correl
specif
gene
function
data
corrobor
highthroughput
sequenc
method
identifi
howev
map
chromatin
chipsequenc
antibodi
footprint
retriev
highli
transcrib
regulatori
nucleosomedeplet
chromatin
region
data
indic
mostli
suppress
chromatin
turn
may
influenc
occup
posit
nucleosom
gener
sequenc
nonrandomli
distribut
mainli
cluster
pivot
genom
region
name
telomer
gene
promot
dna
replic
origin
moreov
put
sequenc
found
code
noncod
region
human
transcriptom
ie
open
read
frame
untransl
gion
utr
telomer
repeatcontain
rna
evid
suggest
like
involv
regul
differ
biolog
pathway
replic
transcript
translat
genom
instabl
past
year
resolut
structur
employ
novel
visual
approach
help
research
valid
previou
comput
predict
disclos
new
aspect
multifacet
world
eg
effect
occurr
within
patientderiv
cancer
tissu
key
role
pathogenesi
two
incur
neurodegen
diseas
amyotroph
later
sclerosi
frontotempor
dementia
inde
presenc
human
genom
potenti
diseas
modul
extens
investig
result
mani
good
exhaust
review
focus
structur
biolog
role
particularli
telomer
oncogen
promot
besid
human
put
sequenc
found
mammalian
genom
yeast
protozoa
bacteria
virus
therefor
implic
mani
human
infecti
diseas
one
review
publish
possibl
role
antigen
variat
system
bacteria
protozoa
silenc
two
virus
possibl
role
virus
use
oligonucleotid
antivir
agent
discuss
viru
recogn
bind
host
cell
surfac
receptor
step
enter
cell
step
penetr
viral
genom
uncoat
step
dna
rna
natur
determin
genom
replic
step
dna
virus
replic
cell
nucleu
major
rna
virus
replic
cytoplasm
infect
cell
viral
mrna
product
viral
protein
express
cytoplasm
step
newli
synthes
viral
genom
protein
assembl
new
virion
step
releas
outsid
cell
step
sinc
number
report
describ
presenc
viru
genom
boom
past
year
treatment
sever
ligand
shown
potenti
interest
therapeut
activ
aim
present
organ
discuss
uptod
closeup
literatur
virus
class
molecul
shown
antivir
activ
viral
target
particular
first
focu
presenc
propos
function
viru
genom
next
present
class
ligand
report
success
antivir
activ
special
emphasi
structur
physicochem
properti
character
viral
ligand
interact
gener
simplifi
viru
life
cycl
schemat
depict
figur
summari
virus
report
correspond
shown
figur
sinc
use
oligonucleotid
antivir
agent
recent
address
musumeci
et
al
topic
consid
present
review
human
immunodefici
viru
hiv
etiolog
agent
acquir
immun
defici
syndrom
aid
date
affect
million
peopl
worldwid
albeit
current
antiretrovir
therapi
keep
diseas
progress
control
peopl
still
die
hivrel
caus
therebi
necessari
find
altern
effect
antivir
target
hiv
belong
retrovirida
famili
singlestrand
rna
genom
process
viral
retrotranscriptas
newli
form
doublestrand
dna
integr
host
cell
chromosom
form
provir
genom
viral
mrna
new
genom
transcrib
research
genom
quit
product
concern
two
rna
viral
genom
copi
also
integr
provir
genom
specif
viru
follow
inform
shown
virion
structur
dimens
genom
size
organ
schemat
represent
red
dot
locat
viral
genom
mrna
bind
protein
number
assess
bioinformat
analysi
accord
correspond
refer
ligand
report
date
display
antivir
effect
correspond
refer
long
termin
promot
ltr
region
nef
code
region
properli
review
metifiot
et
al
briefli
ltr
promot
character
highli
conserv
grich
sequenc
region
correspond
nfb
bind
site
three
mutual
exclus
structur
form
ie
ltrii
ltriii
ltriv
ltriv
parallel
bulg
ascertain
nuclear
magnet
reson
nmr
character
ltriii
ltriv
exert
opposit
effect
ltr
promot
activ
silenc
ltriii
fold
enhanc
ltriv
stabil
addit
ltr
region
control
two
nuclear
protein
nucleolin
upon
bind
increas
ltr
stabil
thu
silenc
transcript
human
ribonucleoprotein
hnrnp
unwind
ltr
region
decreas
promot
activ
data
suggest
balanc
act
regulatori
mechan
promot
activ
interestingli
sequenc
present
ltr
promot
primat
lentivirus
display
bind
site
transcript
factor
relat
regul
support
role
crucial
control
element
viral
transcript
conserv
throughout
evolut
also
evidenc
region
rna
genom
multipl
highli
stabl
parallel
form
rna
sequenc
dimer
intermolecular
interact
suggest
region
could
repres
addit
point
contact
two
viral
genom
copi
addit
rna
like
contribut
observ
increas
genet
recombin
rate
nef
viral
accessori
protein
essenti
factor
provir
dna
synthesi
establish
persist
state
infect
code
region
locat
end
viral
genom
partial
overlap
ltr
three
sequenc
identifi
conserv
region
gene
grich
sequenc
abl
form
report
hiv
central
dna
flap
overlap
positivestrand
found
protect
preintegr
genom
nucleas
degrad
stabil
hiv
small
molecul
show
antivir
effect
differ
level
ligand
bind
dna
ltr
decreas
viral
transcript
bind
rna
ltr
inhibit
revers
transcript
process
lead
case
strong
antivir
effect
ligandmedi
stabil
nef
induc
nefdepend
antivir
activ
recent
stabil
agent
also
employ
cell
infect
latent
activ
result
strong
antivir
effect
especi
combin
dna
repair
inhibitor
reveal
new
aspect
latent
infect
specif
molecul
use
agent
discuss
antivir
ligand
section
review
herpesvirida
larg
famili
virus
long
linear
doublestrand
dna
genom
among
nine
herpesviru
speci
infect
human
least
five
extrem
widespread
ie
herp
simplex
viru
varicella
zoster
viru
epsteinbarr
viru
ebv
cytomegaloviru
caus
orolabi
genit
herp
chickenpox
shingl
mononucleosi
cancer
adult
infect
least
one
herpesvirus
also
tend
display
latent
recur
infect
viru
remain
part
infect
organ
typic
maintain
genom
extrachromosom
nuclear
episom
recent
genomewid
bioinformat
analysi
reveal
impress
high
densiti
put
sequenc
herpesviru
speci
inde
presenc
experiment
report
ebv
kaposi
sarcoma
associ
herpesviru
kshv
human
herpesviru
establish
lifelong
persist
infect
viral
lifecycl
involv
latenc
reactivationlyt
replic
half
world
popul
suffer
hsv
infect
outcom
may
becom
sever
immunocompromis
patient
therapi
effect
howev
emerg
drugresist
viral
strain
urg
discoveri
antiherpet
drug
innov
mechan
action
genom
character
gccontent
found
contain
numer
highli
stabl
sequenc
mainli
locat
repeat
region
visual
antibodi
infect
cell
differ
time
point
postinfect
shown
form
viru
cycledepend
fashion
viral
form
massiv
cell
nucleu
viral
replic
local
differ
cell
compart
accord
viral
genom
movement
ebv
associ
wellknown
infecti
mononucleosi
also
wider
spectrum
ill
includ
sever
lymphoid
malign
studi
presenc
role
ebv
prove
genom
mainten
protein
ebvencod
nuclear
stimul
viral
dna
replic
recruit
cellular
origin
replic
complex
interact
rna
mrna
rich
g
cluster
abl
fold
parallel
behav
cisact
regul
viral
mrna
translat
produc
ribosom
dissoci
mrna
shown
modul
endogen
present
tcell
epitop
involv
persist
infect
cellular
protein
nucleolin
counteract
mechan
interact
mrna
thu
downregul
protein
express
antigen
present
also
observ
mrna
genom
mainten
protein
known
regul
selfsynthesi
suggest
exploit
structur
regulatori
element
viru
kshv
etiolog
agent
form
kaposi
sarcoma
numer
lymphoprolif
disord
mostli
concern
aid
patient
moment
treatment
lytic
latent
infect
avail
kshv
genom
organ
kb
long
uniqu
region
flank
termin
repeat
rich
g
residu
abl
form
stabl
forward
revers
strand
ubiquit
viru
infect
almost
human
popul
diseas
associ
includ
febril
ill
roseola
infantum
also
known
sixth
childhood
erupt
diseas
reactiv
immunosuppress
individu
associ
advers
clinic
outcom
compris
lifethreaten
enceph
graft
reject
transplant
patient
genom
present
telomer
region
termini
integr
telomer
human
chromosom
integr
consid
one
possibl
mode
latenc
sinc
telomer
fold
structur
may
involv
mechan
integr
inde
stabil
telomer
ligand
inhibit
chromosom
integr
stabil
herpesviru
ligand
led
antivir
activ
inhibit
dna
replic
reduct
late
viral
transcript
observ
ebv
ligand
inhibit
stimul
viral
dna
replic
synthesi
contrast
anoth
ligand
reduc
nucleolin
bind
mrna
turn
result
enhanc
synthesi
antigen
present
treatment
latent
infect
cell
stabil
compound
prove
neg
regul
viral
replic
lead
reduct
kshv
genom
copi
ligand
use
herpesvirus
discuss
antivir
ligand
section
review
dna
virus
human
papillomaviru
hpv
doublestrand
dna
viru
caus
skin
genit
wart
type
cancer
genom
display
sever
grich
sequenc
stabl
form
eight
identifi
hpv
type
howev
hpv
includ
high
risk
hpv
type
respons
major
case
cervic
cancer
hepat
b
viru
hbv
partial
doublestrand
dna
viru
best
known
member
hepadnavirida
famili
caus
hepat
b
diseas
may
lead
cirrhosi
hepatocellular
carcinoma
singl
put
sequenc
discov
promot
region
gene
hbv
genotyp
b
found
fold
intramolecular
hybrid
structur
surprisingli
act
posit
regul
hbv
transcript
reveal
luciferas
report
assay
adenoassoci
virus
aav
singlestrand
dna
virus
parvovirida
famili
aav
current
link
human
diseas
use
deliveri
vector
gene
therapi
recent
studi
report
presenc
aav
genom
dna
bind
protein
nucleophosmin
known
enhanc
aav
infect
directli
interact
put
identifi
locat
within
invert
termin
repeat
region
amongst
rna
virus
put
sequenc
identifi
three
posit
singlestrand
one
name
sever
acut
respiratori
syndrom
coronaviru
sarscov
hepat
c
viru
hcv
zika
viru
zikv
sarscov
belong
famili
coronavirida
genom
kb
one
largest
among
rna
virus
identifi
massiv
outbreak
consid
one
pathogen
coronavirus
human
within
nonstructur
protein
socal
sar
uniqu
domain
sud
play
essenti
role
viral
replic
transcript
found
preferenti
bind
oligonucleotid
may
found
nontransl
region
mrna
code
hostcel
protein
involv
apoptosi
signal
transduct
therefor
propos
interact
may
involv
control
host
cell
respons
viral
infect
hcv
belong
flavivirida
famili
caus
acut
chronic
hepat
possibl
lead
cirrhosi
liver
cancer
bioinformat
biophys
analysi
demonstr
exist
two
highli
conserv
sequenc
c
gene
hcv
zikv
also
includ
famili
flavivirida
transmit
human
mosquito
bite
adult
may
caus
mild
symptom
even
symptomless
may
devast
pregnant
woman
caus
microcephali
unborn
child
sever
sequenc
discov
posit
strand
zikv
genom
conserv
within
flaviviru
genom
suggest
import
role
life
cycl
virus
furthermor
zikv
present
addit
uniqu
utr
region
crucial
initi
viral
replic
negativesens
strand
final
investig
ebola
viru
ebov
marburg
viru
marv
two
neg
singlestrand
rna
virus
belong
filovirida
famili
deadli
pathogen
caus
haemorrhag
fever
human
primat
presenc
sequenc
neg
strand
ebov
marv
assess
fluoresc
probe
zikv
ebolv
went
massiv
outbreak
past
three
year
make
two
danger
agent
viral
epidem
current
decad
figur
virus
investig
display
stabil
ligand
test
virus
thoroughli
describ
section
past
year
much
effort
direct
toward
design
small
molecul
abl
target
lead
promis
potenti
therapeut
especi
cancer
sever
updat
review
describ
use
ligand
target
telomer
oncogen
treat
cancer
despit
consider
achiev
antivir
research
viral
infect
still
repres
major
global
threat
nucleic
acid
research
vol
human
health
caus
signific
morbid
mortal
recurr
onset
drugresist
pathogen
combin
fact
major
virus
still
lack
specif
vaccin
urg
develop
novel
therapeut
approach
manag
viral
diseas
end
ligand
provid
compound
innov
mechan
action
antivir
treatment
valuabl
tool
better
understand
viru
mechan
section
ligand
report
exert
antivir
activ
group
base
chemic
natur
core
descript
discoveri
gener
bind
activ
biolog
effect
cell
initi
provid
antivir
properti
activ
select
discuss
n
n
dimethylamino
phenyl
amino
bi
propanamid
label
figur
date
one
studi
ligand
outcom
complex
thorough
medicin
chemistri
investig
start
introduct
acridin
moieti
new
chromophor
research
binder
read
colleagu
demonstr
acridin
core
activ
previous
develop
anthraquinon
core
presenc
nitrogen
atom
heterocycl
scaffold
could
proton
physiolog
condit
result
electron
defici
chromophor
increas
consequ
enhanc
interact
indepth
structureact
relationship
sar
analysi
support
molecular
model
techniqu
next
led
develop
biand
trisubstitut
deriv
class
compound
character
central
planar
pharmacophor
bind
gtetrad
throughinteract
figur
addit
two
side
chain
function
tertiari
amin
moieti
need
interact
groov
amin
group
crucial
activ
sinc
proton
physiolog
ph
disrupt
substitut
bulki
residu
acridin
emerg
potent
compound
among
possibl
regioisomer
seri
evalu
prove
act
telomeras
inhibitor
show
telomeras
inhibit
nanomolar
concentr
higher
affin
respect
duplex
dna
lower
cytotox
compar
first
gener
acridin
induc
longterm
growth
arrest
replic
senesc
breast
carcinoma
cell
line
first
ligand
prove
anticanc
activ
vivo
human
tumor
xenograft
model
use
viral
environ
first
analyz
ebv
investig
function
biochem
characterist
result
show
stabil
viral
rna
infect
abl
reduc
ebv
genom
copi
number
raji
cell
also
found
induc
modest
reduct
transcript
level
inhibit
dna
replic
data
indic
molecul
block
function
critic
viral
dna
replic
ltr
promot
region
provir
genom
abl
significantli
stabil
natur
occur
ltrii
ltriii
induc
addit
ltriv
presenc
increas
concentr
ltr
promot
activ
decreas
almost
respect
untreat
control
activ
detect
mutat
sequenc
unabl
fold
result
confirm
mechan
action
activ
ic
test
variou
cell
line
differ
viral
strain
demonstr
mediat
sinc
structur
also
form
preintegr
viral
rna
dual
mode
action
preand
postintegr
level
propos
figur
antivir
activ
test
confirm
latent
infect
cell
acridin
abl
reduc
viral
titer
undetect
level
also
longterm
treatment
exert
stabil
activ
also
genom
multipl
form
treatment
led
signific
antivir
effect
ic
reduct
viral
dna
synthesi
late
protein
product
moreov
use
infect
cell
evalu
abil
ligand
impair
viral
integr
telomer
region
stabil
telomer
interestingli
telomeras
express
cell
line
frequenc
chromosom
integr
reduc
upon
treatment
howev
effect
ligand
replic
gene
express
yet
discov
recent
employ
luciferas
report
assay
analyz
role
hbv
enhanc
promot
activ
suggest
posit
regulatori
role
hbv
transcript
despit
good
solubl
aqueou
solut
strong
bind
poor
permeabl
across
biolog
barrier
character
ligand
restrain
pharmacolog
applic
nonetheless
still
consid
refer
compound
research
cation
porphyrin
compound
porphin
figur
propos
binder
suitabl
physic
properti
molecular
size
planar
core
posit
charg
hydrophob
favor
stack
g
tetrad
figur
biophys
analysi
demonstr
actual
abl
stack
stabil
parallel
antiparallel
mild
select
quadruplex
duplex
dna
sinc
wide
employ
tool
studi
especi
avail
neg
control
compound
figur
structur
isom
residu
porphin
core
intriguingli
steric
hinder
extern
stack
respect
produc
biolog
effect
biolog
assay
shown
inhibit
human
telomeras
ic
downreg
ulat
protooncogen
cmyc
express
well
sever
cmycregul
gene
contain
sequenc
modul
result
vivo
antitumor
activ
differ
model
porphyrin
abl
decreas
tumor
growth
prolong
surviv
virus
shown
stabil
nef
code
region
induc
format
within
doublehelix
conform
interestingli
tzmbl
report
cell
line
support
nefdepend
replic
porphyrin
inhibit
viral
infect
dosedepend
manner
addit
administr
abl
block
viral
replic
two
differ
jurkatderiv
tcell
line
establish
latenc
bambara
research
group
demonstr
antivir
activ
coupl
increas
rate
apoptosisdeath
compar
untreat
cell
effect
enhanc
associ
dna
damag
repair
inhibitor
hcv
found
stabil
rna
inhibit
hcv
c
gene
express
mechan
action
confirm
enhanc
green
fluoresc
protein
report
gene
system
addit
infecti
hcv
cultur
system
administr
porphyrin
led
dosedepend
decreas
viral
rna
level
also
employ
investig
role
ebov
l
gene
exert
high
stabil
target
rna
circular
dichroism
rna
stop
assay
importantli
treatment
increas
concentr
compound
transcript
l
gene
gradual
reduc
confirm
target
select
mutant
sequenc
use
neg
control
produc
signific
inhibit
transcript
addit
porphyrin
found
inhibit
replic
ebov
minigenom
cellbas
approach
use
firefli
luciferas
report
protein
thu
use
effici
antivir
screen
system
worth
note
low
select
toward
structur
versu
duplex
dna
may
suggest
antivir
activ
ascrib
multipl
mechan
action
limit
biolog
clinic
applic
perylen
repres
wellknown
famili
ligand
contain
differ
substitut
larg
fuse
aromat
ring
system
character
hydrophob
heptacycl
central
core
respons
bind
g
quartet
throughinteract
four
proton
side
chain
accur
sar
studi
scaffold
point
two
crucial
featur
bind
basic
system
prevent
compound
selfaggreg
distanc
aromat
central
core
quaternar
nitrogen
residu
side
chain
modul
ligand
solubl
affect
recognit
cation
amino
moieti
later
substitu
thought
regul
specif
versu
duplex
dna
piper
n
nbi
ethyl
diimid
figur
lead
compound
class
shown
induc
stabil
structur
telomer
lead
telomer
shorten
reduct
cell
prolifer
tumorigen
senesc
effort
improv
physicochem
properti
perylen
scaffold
progress
surfac
reduct
led
promis
class
naphthalen
diimid
ndi
deriv
inde
demonstr
dimens
planar
core
modul
abil
class
compound
recogn
differ
dna
conform
particular
cyclic
condens
system
least
four
ring
requir
effici
target
addit
ndi
planar
core
accommod
four
side
chain
enhanc
affin
compound
found
inhibit
telomeras
activ
low
micromolar
rang
produc
shortterm
cell
growth
inhibit
cancer
cell
line
improv
dna
alkyl
properti
modif
introduc
ndi
scaffold
includ
quinon
methid
precursor
ligand
reveal
revers
irrevers
bind
properti
toward
telomer
dna
promis
duplex
versu
quadruplex
select
found
impair
growth
differ
telomeraseposit
cancer
cell
line
follow
telomeras
activ
inhibit
crystallograph
analys
variou
nditelomer
complex
provid
turn
point
ration
optim
class
compound
neidl
et
al
report
test
ligand
promot
parallel
topolog
form
complex
oligonucleotid
stoichiometri
result
combin
bind
site
affin
direct
groov
interact
highli
influenc
proton
moieti
side
chain
interact
dna
phosphat
groov
despit
high
molecular
weight
ndi
highli
versatil
structur
suitabl
medicin
chemistri
modif
improv
pharmacolog
profil
antivir
field
piper
induc
stabil
structur
nef
code
region
genom
howev
best
result
obtain
coreextend
ndi
deriv
cexndi
figur
seri
compound
endow
except
solubl
properti
obtain
fuse
ndi
core
heterocycl
interestingli
newli
develop
ligand
display
greater
vitro
bind
stabil
activ
viral
ltr
human
telomer
sequenc
use
cellular
refer
importantli
cexndi
exhibit
promis
antivir
activ
low
nanomolar
rang
ic
nm
differ
strain
low
cytotox
yield
wide
encourag
therapeut
window
mechan
action
prove
combin
timerel
antivir
report
assay
use
ltrmutant
sequenc
control
reason
higher
antivir
activ
depend
select
toward
viral
infect
ltr
telomer
like
abund
speci
cell
activ
cexndi
also
analyz
infect
vitro
cd
taqpolymeras
stop
assay
indic
compound
abl
bind
stabil
variou
sequenc
genom
mass
spectrometri
competit
analysi
reveal
stronger
prefer
gener
viral
preferenti
bound
compar
telomer
inde
cexndi
show
remark
antivir
activ
ic
nm
antiherpet
effect
ascrib
inhibit
viral
dna
replic
gather
timeofaddit
assay
flow
cytometri
analysi
use
acyclovir
refer
compound
sinc
cexndi
select
toward
vitro
result
good
outstand
mark
activ
like
due
also
massiv
presenc
viral
cell
nucleu
demonstr
occur
replic
pyridostatin
pd
figur
ration
design
structur
featur
share
known
ligand
compris
potenti
planar
electronrich
aromat
surfac
abil
particip
hydrogen
bond
moreov
rotat
bond
provid
flexibl
degre
make
pd
capabl
adapt
dynam
pd
strongli
stabil
telomer
effect
doublestrand
dna
result
shelterin
complex
integr
alter
trigger
dnadamag
respons
telomer
numer
modif
introduc
pd
scaffold
explor
role
class
anticanc
therapi
inde
obtain
analogu
show
remark
growthinhibitori
effect
cancer
cell
line
complet
arrest
longterm
exposur
drug
result
emphas
high
potenti
compound
finetun
biolog
activ
antivir
research
pd
use
studi
role
ebv
mrna
enhanc
stabil
sequenc
decreas
synthesi
level
concentrationdepend
fashion
vitro
vivo
consequ
ebvinfect
cell
result
less
effici
recogn
virusspecif
cell
albeit
mechan
action
still
need
clarifi
hbv
pd
use
unravel
posit
regulatori
role
within
gene
promot
pd
analogu
name
pdp
figur
employ
hcv
research
along
pdpinduc
stabil
structur
locat
hcv
rna
downregul
c
gene
express
vivo
pdp
inhibit
intracellular
replic
differ
hcv
genotyp
confirm
mechan
action
result
antivir
activ
low
micromolar
rang
bisquinolinium
compound
character
aromat
nucleu
substitut
two
proton
quinolin
moieti
first
report
compound
present
dicarboxamidepyridin
triazin
ring
central
core
promis
ligand
shown
increas
stabil
telomer
great
select
duplex
dna
compound
abl
adopt
intramolecular
synsyn
hbond
propos
critic
recognit
like
consequ
rigid
compound
promot
gquartet
overlap
base
central
core
expand
without
disrupt
hbond
lead
new
seri
display
except
select
due
crescentlik
shape
prevent
compound
intercal
duplex
dna
figur
figur
best
repres
class
potent
telomer
ligand
abl
reduc
telomeras
process
use
kshv
evalu
potenti
role
inhibit
latent
viral
replic
ligand
found
elicit
stress
respons
infect
cell
stall
replic
machineri
lead
lag
strand
kshv
genom
furthermor
treatment
result
dramat
reduct
episom
copi
number
effect
cell
growth
prolifer
data
repres
first
use
ligand
target
latent
viral
infect
also
use
ebv
prevent
bind
nucleolin
mrna
increas
endogen
level
ebvinfect
b
cell
cell
deriv
nasopharyng
carcinoma
result
indic
mrna
interact
also
target
antivir
summari
ligand
virus
test
report
figur
last
decad
research
role
human
genom
quit
challeng
promis
lead
awar
highord
structur
nucleic
acid
research
vol
play
key
regulatori
role
biolog
pathway
transcript
replic
translat
telomer
mainten
develop
binder
encourag
anticanc
activ
prompt
research
identifi
new
way
exploit
structur
human
diseas
eg
viral
infect
present
cell
viru
genom
challeng
develop
antivir
ligand
reason
consist
overcom
select
toward
viral
versu
cellular
major
limit
far
describ
ligand
larg
flat
aromat
core
stack
g
tetrad
reduc
chanc
discrimin
among
differ
moreov
gener
character
highmolecular
weight
proton
side
chain
necessari
loop
groov
interact
hand
may
affect
cellular
uptak
inde
low
select
profil
poor
druglik
properti
ligand
advanc
beyond
phase
ii
drug
discoveri
pathway
quarfloxin
fluoroquinolon
deriv
compound
develop
hurley
research
group
date
ligand
reach
phase
ii
clinic
trial
withdrawn
due
bioavail
relat
problem
howev
sever
data
present
literatur
indic
gener
certain
degre
select
achiev
toward
viral
interest
comparison
telomer
ie
abund
cellular
case
cexndi
compound
higher
affin
toward
viral
structur
like
caus
extens
ndi
core
thu
interact
viral
loop
region
uniqu
gener
loop
groov
region
character
thu
amen
select
recognit
structur
studi
cellular
ligand
complex
indic
molecul
interact
quasiextern
stack
heteroaromat
chromophor
small
molecul
isstack
onto
face
extern
gquartet
figur
onto
side
chain
posit
groov
therefor
conceiv
report
antivir
activ
ligand
mediat
increas
interact
henc
affin
grooveloop
moieti
viral
date
one
viral
structur
resolv
nmr
spectroscopi
therefor
futur
nmr
crystallograph
resolut
viral
ligand
complex
necessari
defin
viral
architectur
could
help
research
identifi
possibl
uniqu
structur
could
lead
design
develop
select
molecul
case
ligand
show
signific
select
viral
versu
telomer
present
oncogen
promot
usual
strongli
bound
test
compound
nonetheless
data
far
present
antivir
use
ligand
shown
gener
promis
activ
wide
rang
viru
speci
one
possibl
explan
amount
viral
infect
cell
larg
surpass
cellular
inde
usual
cell
exploit
function
factori
product
new
viral
genom
eventu
assembl
new
matur
viru
particl
see
figur
viral
infect
cycl
thu
conceiv
viral
becom
larg
abund
cellular
viru
replic
least
one
case
eventu
demonstr
sharp
increas
number
viral
viral
dna
replic
combin
abund
per
genom
number
new
genom
amount
viral
could
outstand
cellular
sever
log
per
cell
addit
far
identifi
viral
usual
key
regulatori
element
viru
life
cycl
stabilizationunfold
ligand
like
explain
result
massiv
viru
inhibit
behaviour
demonstr
also
virus
would
possibl
exploit
ligand
strictli
select
viral
scenario
would
highli
rapidli
expand
research
pharmacolog
applic
ligand
antivir
agent
point
address
necess
standard
method
studi
antivir
activ
ligand
one
start
point
detect
inhibitori
activ
ligand
viru
life
cycl
effect
obtain
investig
mechan
action
perform
regard
time
addit
method
assist
indic
last
viral
step
compound
activ
thu
narrow
possibl
molecular
target
howev
complex
uniqu
viru
investig
target
mechan
action
molecular
level
may
straightforward
exampl
pd
inhibit
synthesi
vitro
cell
cell
led
exact
opposit
effect
ie
enhanc
synthesi
like
multipl
mechan
involv
observ
outcom
final
target
viral
genom
lead
excit
possibl
affect
virus
undergo
latenc
virus
hiv
herp
papilloma
viru
famili
compris
initi
acut
infect
subsequ
latent
infect
latter
character
mainten
viru
genom
human
host
entir
life
host
latent
viru
may
reactiv
time
time
produc
new
matur
viru
current
therapi
normal
target
viral
protein
fail
remov
latent
viru
ie
viru
genom
host
select
target
viral
genom
approach
would
allow
remov
replic
viru
also
latent
one
therefor
erad
far
incur
infect
agent
pictur
worth
consid
virusinduc
manipul
host
chromatin
recent
year
studi
role
chromatin
viral
infect
show
dynam
virushost
chromatin
interact
chromatin
machineri
modul
viru
encod
protein
exampl
epigenet
regul
viral
chromatin
viral
gene
product
play
key
role
determin
whether
viru
develop
lytic
latent
infect
consid
recent
evid
report
et
al
format
reflect
suppress
role
heterochromatin
occur
highli
transcrib
regulatori
nucleosomedeplet
chromatin
region
would
interest
understand
viru
affect
could
affect
complex
mechan
conclud
data
report
review
indic
structur
crucial
element
regul
virus
life
cycl
lytic
latent
state
ii
ligand
effici
act
antivir
agent
encourag
research
continu
investig
small
molecul
matter
fact
albeit
quarfloxin
clinic
evalu
progress
success
phase
clinic
trial
ie
optim
toxic
profil
suggest
improv
ligand
pharmacolog
profil
like
lead
concret
clinic
applic
compound
therefor
research
next
futur
need
improv
understand
activ
regul
viral
level
ii
select
ligand
toward
viral
versu
cellular
iii
druglik
properti
antivir
ligand
employ
vivo
studi
antivir
drug
may
repres
signific
turn
point
manag
viral
infect
especi
peopl
access
immun
like
immunocompromis
patient
elderli
peopl
addit
antivir
effect
report
latent
infect
may
pave
way
cuttingedg
therapeut
approach
treatment
human
fatal
malign
relat
latent
virus
aid
herpesand
hpvrelat
cancer
